

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Health Technology Evaluation

### Durvalumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID6220]

#### Final scope

##### Remit/evaluation objective

To appraise the clinical and cost effectiveness of durvalumab with chemotherapy and durvalumab monotherapy within its marketing authorisation for neoadjuvant and adjuvant treatment of resectable non-small-cell lung cancer (NSCLC).

##### Background

Lung cancer is the third most common cancer and the most common cause of cancer death in the UK, accounting for 13% of all new cancer cases and 21% of all cancer deaths between 2017 and 2019.<sup>1</sup> Most lung cancers are diagnosed at an advanced stage when the cancer has spread to lymph nodes and other organs in the chest (locally advanced disease; stage 3) or to other parts of the body (metastatic disease; stage 4). Less than 30% of lung cancers are diagnosed at an early stage (stage 1 or 2).<sup>2</sup>

In 2021, 91% (31,374) of people diagnosed with lung cancer in England had NSCLC.<sup>2</sup> Of these people, 17% (5,333) had surgical treatment for their cancer.<sup>2</sup> Despite the curative intent of treatment for early-stage lung cancer, survival is poor, with only about 57% people with stage 1, 34% with stage 2 and 13% with stage 3 surviving for 5 years after diagnosis.<sup>3</sup> It is estimated that over half of all NSCLCs express the programmed cell death ligand-1 (PD-L1) biomarker.<sup>4</sup> Cancer cells expressing PD-L1 are believed to suppress certain immune responses which results in a weaker anti-tumour response.<sup>4,5</sup>

The treatment pathway for NSCLC can be divided into interconnected decision points based on the number staging system and line of therapy. Treatment choices are influenced by the presence of biological markers (including programmed cell death 1 ligand PD-L1 status), oncogenic driver genetic alterations, histology (squamous or non-squamous) and previous treatment. [NICE's Technology Appraisal Pathway Pilot scope for treatments for non-small-cell lung cancer](#) outlines in more detail the NSCLC treatment pathway.

NICE guideline 122 (NG122) '[Lung cancer: diagnosis and management](#)' recommends surgery, radiotherapy, chemoradiotherapy or a combination of these for stage 1 to 2 NSCLC. People may be offered a neo-adjuvant (before surgical removal of cancerous tumour) treatment which could be platinum based chemotherapy, or nivolumab with chemotherapy as recommended by NICE [TA876](#). Neoadjuvant chemotherapy has shown equivalent outcomes in terms of survival to adjuvant chemotherapy.<sup>6</sup>

For stage 3 NSCLC, surgery is carried out if the surgeon deems the tumour to be resectable. Before surgery, chemoradiotherapy (chemotherapy with radiotherapy) may be used or surgery may potentially be followed by chemotherapy. If well enough,

Final scope for the evaluation of durvalumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID6220]

people may be offered a cisplatin-based chemotherapy (adjuvant treatment) after surgery.

People who have had surgery may have an adjuvant treatment. NICE [TA761](#) recommends osimertinib in the Cancer Drugs Fund as adjuvant treatment for people whose cancer has an EGFR exon 19 deletion or an exon 21 (L858R) substitution mutation. For people whose cancer does not have an EGFR mutation, platinum chemotherapy may be offered as adjuvant treatment. NICE [TA823](#) recommends atezolizumab in the Cancer Drugs Fund as an option for maintenance treatment after complete tumour resection in adults with stage 2 to 3a NSCLC and adjuvant chemotherapy.

### The technology

Durvalumab (Imfinzi, AstraZeneca) with chemotherapy then durvalumab monotherapy does not currently have a marketing authorisation in the UK for neoadjuvant and adjuvant treatment of resectable NSCLC. It is being studied in clinical trials in combination with platinum based chemotherapy compared with platinum based chemotherapy as a neo-adjuvant and adjuvant therapy in those with locally advanced NSCLC.

Durvalumab currently has a marketing authorisation for treatment of locally advanced, unresectable NSCLC in adults whose tumours express PD-L1 on 1% or more of tumour cells and whose stage 3 disease has not progressed following platinum-based chemoradiation therapy.

<b>Interventions</b>	Durvalumab with chemotherapy for neoadjuvant treatment then durvalumab monotherapy for adjuvant treatment
<b>Population(s)</b>	People with untreated resectable non-small-cell lung cancer which has no EGFR or ALK genetic alterations
<b>Subgroups</b>	If the evidence allows subgroups will be considered based on: <ul style="list-style-type: none"><li>• Whether durvalumab is used before and after surgery</li><li>• PD-L1 tumour proportion score</li><li>• Disease stage</li></ul>

<b>Comparators</b>	<p>Established clinical management without durvalumab, which may include</p> <ul style="list-style-type: none"> <li>• Neoadjuvant nivolumab with chemotherapy</li> <li>• Neoadjuvant chemoradiotherapy</li> <li>• Platinum-based chemotherapy</li> <li>• Active monitoring</li> <li>• Pembrolizumab (subject to NICE appraisal)</li> </ul> <p>For people whose tumours express PD-L1 with at least a 50% tumour proportion score</p> <ul style="list-style-type: none"> <li>• Atezolizumab after adjuvant cisplatin-based chemotherapy (subject to NICE appraisal)</li> </ul>
<b>Outcomes</b>	<p>The outcome measures to be considered include:</p> <ul style="list-style-type: none"> <li>• event-free survival</li> <li>• disease-free survival</li> <li>• pathological complete response</li> <li>• response rates</li> <li>• overall survival</li> <li>• adverse effects of treatment</li> <li>• health-related quality of life.</li> </ul>
<b>Economic analysis</b>	<p>The reference case stipulates that the cost effectiveness of treatments should be expressed in terms of incremental cost per quality-adjusted life year.</p> <p>The reference case stipulates that the time horizon for estimating clinical and cost effectiveness should be sufficiently long to reflect any differences in costs or outcomes between the technologies being compared.</p> <p>Costs will be considered from an NHS and Personal Social Services perspective.</p> <p>The availability of any commercial arrangements for the intervention, comparator and subsequent treatment technologies will be taken into account.</p> <p>The availability and cost of biosimilar and generic products should be taken into account.</p>

<p><b>Other considerations</b></p>	<p>Guidance will only be issued in accordance with the marketing authorisation. Where the wording of the therapeutic indication does not include specific treatment combinations, guidance will be issued only in the context of the evidence that has underpinned the marketing authorisation granted by the regulator.</p>
<p><b>Related NICE recommendations</b></p>	<p><b>Related technology appraisals:</b></p> <p><a href="#">Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer</a> (2023) NICE technology appraisal guidance 876</p> <p><a href="#">Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer</a> (2022) NICE technology appraisal guidance 823</p> <p><a href="#">Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection</a> (2022) TA761</p> <p><b>Related technology appraisals in development:</b></p> <p><a href="#">Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer</a> [ID3907] Publication date to be confirmed</p> <p><a href="#">Pembrolizumab for neoadjuvant and adjuvant treatment of resectable stage 2 to 3B non-small-cell lung cancer</a> [ID5094] Publication date to be confirmed</p> <p><a href="#">Atezolizumab with chemotherapy for neoadjuvant and adjuvant treatment of resectable non-small-cell lung cancer</a> [ID3894] Publication date to be confirmed</p> <p><a href="#">Nivolumab for adjuvant treatment of resected non-small-cell lung cancer</a> [ID4053] Publication date to be confirmed</p> <p><a href="#">Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer</a> NICE Technology Appraisals guidance ID1263. Publication date to be confirmed</p> <p><b>Related NICE guidelines:</b></p> <p><a href="#">Lung cancer: diagnosis and management</a> (NG122)</p> <p><b>Related quality standards:</b></p> <p><a href="#">Lung cancer in adults</a> (2019) NICE quality standard 17</p>
<p><b>Related National Policy</b></p>	<p>The NHS Long Term Plan, 2019. <a href="#">NHS Long Term Plan</a></p> <p>NHS England (2018/2019) <a href="#">NHS manual for prescribed specialist services (2018/2019)</a> Chapter 105: Specialist cancer services (adults).</p>

Final scope for the evaluation of durvalumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID6220]

## References

1. Cancer Research UK (2023). [Lung cancer statistics](#). Accessed October 2023
2. Royal College of Surgeons of England (2023). [National Lung Cancer Audit: State of the Nation Report 2023](#). Accessed November 2023
3. Office for National Statistics. Cancer Survival in England: adults diagnosed between 2013 and 2017 and followed up to 2018. 2019. Available from: <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/cancersurvivalratescancersurvivalinenglandadultsdiagnosed>. Accessed October 2023
4. Skov, B., Rørvig, S., Jensen, T. et al. (2020) The prevalence of programmed death ligand-1 (PD-L1) expression in non-small cell lung cancer in an unselected, consecutive population. *Mod Pathol* 33, 109–117
5. Han Y, Liu D, Li L. [PD-1/PD-L1 pathway: current researches in cancer](#). *Am J Cancer Res*. 2020 Mar 1;10(3):727-742. PMID: 32266087; PMCID: PMC7136921.
6. European Society for Medical Oncology (ESMO). Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*. 2017;28(Supplement 4):iv1–iv21. Available from: <https://www.esmo.org/Guidelines/Lung-and-Chest-Tumours/>. Accessed October 2023